RxDoctor Payments Data

Daniel Eslinger

Psychiatric/Mental Health · Walla Walla, WANPI 1952350563

Payments from drug & device makers

$821in general payments, 2019–2025

Across 50 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$328
  • Teva Pharmaceuticals USA, Inc.$116
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
  • Takeda Pharmaceuticals U.S.A., Inc.$65
  • Alkermes, Inc.$52
  • Johnson & Johnson$42
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$77494%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$821 in reported general payments places this provider in the 70th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$50,925
Medicare patients
85
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$137,612
Invega SustennaPaliperidone Palmitate27$90,336
RexultiBrexpiprazole27$48,279
VraylarCariprazine Hcl12$16,321
Lurasidone Hcl57$15,394
Ziprasidone Hcl214$14,616
Gabapentin329$8,593
NamzaricMemantine Hcl/Donepezil Hcl14$6,898
TrintellixVortioxetine Hydrobromide12$5,914
Duloxetine Hcl314$5,112
Paliperidone ErPaliperidone15$5,013
Bupropion XlBupropion Hcl290$4,216
Divalproex Sodium ErDivalproex Sodium51$3,136
Quetiapine Fumarate187$3,020
Buspirone Hcl85$2,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$137,61217 claims
Johnson & JohnsonInvega Sustenna$42$90,33627 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$48,27927 claims
AbbVieVraylar, Namzaric$11$23,21926 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$65$5,91412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →